Overview

PI-88 in Hepatocellular Carcinoma After Hepatectomy

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of PI-88 to inhibit or reduce tumor recurrence in patients with hepatocellular carcinoma following hepatectomy.
Phase:
Phase 2
Details
Lead Sponsor:
Medigen Biotechnology Corporation
Progen Pharmaceuticals
Collaborators:
Medigen Biotechnology Corporation
Progen Pharmaceuticals